Company intelligence / Profile preview

Cambium Plant Sciences

Goderich, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

Cambium is developing next-generation cannabis genetics, focusing on disease resistance and premium yield; currently retrofitting a 34,000 sqft R&D facility; not conducting clinical trials

Industry: Non-Drug Biotech

Partnerships

In-house brands (notably 7ACRES)domestic and global cultivation and manufacturing partners

Beyond the preview

Go deeper on Cambium Plant Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cambium Plant Sciences.

Explore the full profile